With such an approach, epigenetics biomarkers are becoming close to clinical reality, as demonstrated by the example of the circulating, cell-free, DNA-based epigenetic biomarker methylated Septin9, which shows great promise as a tool to diagnose HCC in patients with cirrhosis [129]. This evidence concerns the gene SEPTIN9 and Cirrhosis.